Live Breaking News & Updates on Glp 1 receptor agonist

Stay updated with breaking news from Glp 1 receptor agonist. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Semaglutide improves symptoms and function in obesity-related heart failure

1. Semaglutide showed significant improvements in KCCQ-CSS score and reduction in body weight compared to placebo. 2. There were fewer serious adverse events in the semaglutide group. Evidence Rating Level: 1 (Excellent) Study Rundown: Obesity and diabetes lead to poor prognosis in patients with heart failure. GLP-1 receptor agonists, such as semaglutide, have been shown

Rating-level , Obesity-related-heart-failure , Between-mar , Glp-1-agonist , Glp-1-receptor-agonist , Glucagon-like-peptide-1-glp-receptor-agonists , Heart-failure , Hfpef , Hfpef-heart-failure-with-preserved-ejection-fraction , Obesity , Semaglutide

Ozempic could boost the gym industry

Equinox, Life Time Fitness, and Xponential Fitness have all started offering Ozempic and other GLP-1-related products this year

United-states , Michael-crandall , Lars-fruergaard-jorgensen , Life-time-fitness , Novo-nordisk , Morgan-stanley , Bloomberg , Fruergaard-jorgensen , Hudson-yards , Xponential-fitness , Time-fitness , Pure-barre

Ozempic hits booze sales, Moderna likes AI, Biogen's blockbuster drug

Plus, Bernie Sanders launches an investigation into Wegovy and Ozempic prices, and Bristol-Myers Squibb prepares to lose lucrative patents

Bristol-myers-squibb , Novartis , Astrazeneca , Wall-street , Biogen , Iogen , Oderna , Penai , Ovartis , Erck , Egovy

Ozempic users spend less money at restaurants, survey finds

63% of survey respondents said they are spending less eating out at restaurants since they started taking the medication

Lars-fruergaard-jorgensen , Morgan-stanley , Novo-nordisk , Wendy , Bloomberg , Fruergaard-jorgensen , Business , Inance , Irzepatide , Ealth , Edical , Harma

Ozempic-like drug may slow Parkinson's, small study shows

A new, small study suggests medication similar to the blockbuster weight-loss drugs Ozempic and Wegovy could slow the ravages of Parkinson's disease.

United-states , New-york , France , French , Michael-okun , Olivier-rascol , Hyun-joo-chu , Wassilios-meissner , National-institute-of-neurological-disorders , University-of-toulouse , University-of-florida , New-york-times